Business Categories Reports Podcasts Events Awards Webinars
Contact My Account About

2025 Beauty Deals: Fewer, Bigger, More Strategic

Published February 26, 2026
Published February 26, 2026
Slashio Photography via Unsplash

Beauty dealmaking in 2025 didn’t move in a straight line—but it did end the year on a steady footing. The BeautyMatter Deal Index tracked 263 transactions, down 11.5% from 2024, yet broadly consistent with 2023 levels. The decline in volume, however, tells only part of the story. This was a year defined less by frenetic activity and more by precision: fewer deals, but more intentional ones. Even amid a noisy macro backdrop—tariff anxiety, inflation pressure, and persistent questions around consumer demand—beauty continued to prove itself one of the most durable corners of the broader consumer landscape. And while the headlines were dominated by uncertainty, the market quietly kept moving, with enough meaningful transactions to sustain momentum and keep both strategics and investors engaged.

What stood out most was the strategic clarity behind the deals that did get done—and the valuation confidence that often accompanied them. Many of 2025’s most consequential transactions weren’t simply about buying growth; they were about acquiring capabilities, expanding channels, and positioning for the next phase of category evolution. At the same time, the long-discussed convergence of beauty and wellness stopped being an industry talking point and became a measurable business strategy, increasingly reflected in the targets attracting premium interest. Taken together, 2025 reads less like a slowdown and more like a recalibration: a market that rewarded quality over quantity, and one that enters 2026 with a broader buyer universe, sharper strategic intent, and a deal environment that looks more constructive than the volume numbers alone would suggest.

2025 Deal Activity by the Numbers

The BeautyMatter Deal Index tracked 263 transactions in 2025, marking an 11.5% decline compared to 2024. Growth investments were consistent year over year with 2024, but M&A activity fell 21.0%.

During the year, the top-performing categories in terms of deal activity were brand portfolio (up 84.6%), color cosmetics (up 31.3%), professional (up 21.7%), men’s + grooming (up 20.0%), and retail (up 13.6%). Category laggards included personal care (down 67.9%), funds + platforms (down 62.5%), fragrance (down 35.3%), haircare (down 27.8%), skincare (down 23.5%), supply side (down 17.9%), technology (down 7.7%), and health + wellness (down 3.7%).

2025 Deals to Know

Of the 263 deals tracked by the BeautyMatter Deal Index in 2025, here are the deals people were talking about:

Category | Selected Deals

Brand Portfolio
Q1

Q4

  • L'Oréal’s acquisition of Kering Beauté, its largest acquisition ever
  • Kimberly-Clark's acquisition of Kenvue

Color Cosmetics
Q1

Q2

  • Freck’s acquisition by a nameless group of investors in what appears to be a distressed sale
  • Wonderskin’s $50 million Series A by Insight Partners

Q3

Q4

  • Anastasia Soare’s growth investment and buyout of TPG in Anastasia Beverly Hills
  • YSE Beauty’s growth investment by Silas Capital, L Catterton, Willow Growth Partners, and Halogen Ventures

Fragrance
Q1

  • Tru Fragrance’s acquisition of Lake & Skye
  • L'Oréal’s minority investment in Amouage
  • General Atlantic and Mona Kattan’s acquisition of Kayali
  • Interparfums’ acquisition of Maison Goutal from Amorepacific

Q2

  • DedCool’s follow-on growth investment by Sandbridge Capital

Q4

  • Homecourt’s growth investment by Cult Capital
  • Noted Aromas’ acquisition by eComplete and NVM Private Equity

Funds + Platforms
Q2

Q4

  • The launch of Veralis Group by long-time Unilever executive, Vasiliki Petrou

Haircare
Q1

  • Sandbridge Capital’s growth investment in Everist
  • The acquisition of Carol’s Daughter by brand founder Lisa Price and an unnamed investor

Q2

Q3

  • Odele’s growth investment by Stride Consumer Partners

Q4

  • KilgourMD’s growth investment by Willow Growth Partners, Joyance Partners, and Able Partners
  • Foltène’s acquisition by Chinese platform Joy GroupIndian haircare brand Moxie Beauty’s growth investment by Bessemer Venture Partners and Fireside Ventures

Health + Wellness
Q1

Q2

  • Hims & Hers’ $1 billion growth financing through a convertible note offering
  • Veracity’s Series A financing by Maveron and Melitas Ventures

Q3

  • Eight Sleep’s growth investment by HSG, Valor Equity Partners, and others
  • Alice Mushrooms’ Series A by NewBound Ventures and Unilever Ventures

Q4

  • Perelel’s growth investment by Prelude Growth Partners, Willow Growth Partners, Unilever Ventures, and Selva Ventures
  • Indian Ayurvedic brand Kapiva’s late-stage growth investment by 360 ONE Asset, Vertex Growth, 3one4 Capital
  • Austrian longevity resort operator Lanserhof Group’s late-stage growth investment by AltamarCAM Partners, King Street Capital Management, and Manuel Puig
  • Calming drink brand Trip’s growth investment by Coefficient Capital

Men’s + Grooming
Q1

Q2

Q4

  • Indian grooming brand Bombay Shaving Company’s growth investment by Sixth Sense Ventures and others
  • Indian grooming brand Muuchstac’s acquisition by Godrej Consumer Products Ltd

Personal Care
Q2

  • Touchland’s acquisition by Church & Dwight
  • DUDE Wipes’ growth investment by TSG Consumer and Mark Cuban

Q4

  • Hanni’s growth investment by Melitas Ventures, Cult Capital, and Rodeo GP
  • Edgewell Feminine Care’s acquisition by Essity
  • Dune Suncare’s growth investment by REI Path Ahead Ventures, the venture arm of outdoor retailer REI

Professional
Q1

Q2

Q3

  • FACEGYM’s growth investment by India’s Reliance Retail Ventures
  • Fountain Life’s growth investment by EOS Ventures
  • The majority investment in South Korean hair concept Juno by Blackstone

Q4

  • Wella’s acquisition by KKR from Coty
  • Galderma’s investment by L’Oréal
  • Innerskin’s growth investment by Iris Ventures and Label Capital

Retail
Q1

Q2

  • The Vitamin Shoppe’s acquisition by Kingswood Capital Management
  • Nordstrom’s acquisition by El Puerto de Liverpool and the Nordstrom family

Q3

Q4

  • Scent Bar’s (Luckyscent) acquisition by Monogram Capital
  • Whatnot’s late-stage growth investment by CapitalG, DST Global, and others
  • ShopMy’s growth investment by Avenir Growth, Bain Capital Ventures, Bessemer Venture Partners, Menlo Ventures
  • UK retailer Bodycare’s acquisition out of administration by an investment group led by Charles Denton

Skincare
Q1

Q2

  • Medik8’s acquisition by L’Oréal
  • Rhode’s acquisition by e.l.f. Beauty
  • Skin Rock’s growth investment by Redrice Ventures and JamJar Investments

Q3

  • OSEA’s growth investment by General Atlantic
  • Byoma’s majority investment by Bansk Group
  • Magic Molecule’s investment by NexPhase Capital
  • Amala’s acquisition by Fundamental Brands
  • Biophyto Genesis’ acquisition by Chinese platform Joy Group
  • OneSkin’s growth investment by Prelude Growth Partners

Q4

  • Rohto Pharmaceutical’s acquisition of the Japanese trademark of Obaji from Waldencast
  • Rare Beauty Brands’ acquisition of Kate Somerville

Supply Side
Q1

Q3

  • Belle Aire Creations’ acquisition by Givaudan
  • Samhwa’s acquisition by KKR
  • Debut’s growth investment by Fine Structure Ventures, L’Oréal BOLD, and others
  • Purvala’s acquisition by Olaplex
  • Geltor’s growth investment by Starlight Ventures
  • Boox’s acquisition by FabFitFun

Q4

Technology
Q1

  • Later’s acquisition of MavelyDaash’s seed roundInfinite Reality’s acquisition of Obsess
  • Swanlaab Venture Factory’s growth investment in Flowww

Q3

  • Flex’s growth investment by First Round and others
  • Iris Finance’s seed investment by Glasswing Ventures and others
  • YASO’s growth investment by Puma Growth Partners and others

Q4

  • Japan-based creator studio NADESHIKO’s acquisition by Anymind

Brand Failures

The Index also tracked 22 brand failures throughout the year (a combination of bankruptcies and shutdowns). Here are a few notable ones:

Quarter | Selected Brand Failures
Q1
Brand Agency London’s fall into administration; Hims & Hers' shutdown of Apostrophe; the shutdown of slugging brand, Futurewise; and the bankruptcy of Opulus Beauty Labs

Q2
Informa’s shutdown of FounderMade; the liquidation of Kate Moss’s beauty brand Cosmoss; the liquidation of clean beauty pioneer Juice Beauty; and Unilever’s shutdown of REN Clean Skincare

Q3
The shutdowns of Flower Beauty, Ami Colé, Youthforia, MakeupAlley, social retail platform Flip (which once had a valuation of $1 billion), SKKN by Kim, and Faace; the bankruptcy filing of British beauty retailer Bodycare
Q4

The bankruptcy of the brand portfolio Valley of the Sun Cosmetics, and German retailer Parfümerie Pieper

The 22 brand failures tracked in 2025 compare with 25 in 2024 and 28 in 2023—evidence that the sector’s attrition rate has remained stubbornly consistent over the past three years, even as deal volume fluctuated. In other words, while beauty continues to outperform many consumer categories, it is not immune to structural pressure—and the market has become far less forgiving.

These failures reflect a convergence of challenges that are increasingly systemic rather than cyclical: faster-shifting consumer preferences, heightened shopper selectivity, and a cost environment that has reset expectations across everything from inventory to customer acquisition. Just as importantly, they underscore a capital market that has moved from growth at all costs to disciplined underwriting. In a highly selective funding environment, brands without clear differentiation, strong unit economics, and a credible path to profitability are finding that time—and liquidity—runs out quickly.

Eight Dynamics and Trends That Will Define Beauty Investments + M&A in 2026

1. Portfolio Optimization Will Create Both Orphans and Opportunities

Portfolio pruning will remain a primary driver of PE and strategic activity, with more groups actively divesting non-core assets—sometimes at distressed valuations, sometimes at surprisingly attractive ones. This dynamic will create fertile ground for new platform builders and opportunistic buyers, particularly as large strategics continue to simplify and refocus. Many of the brands that were once the darlings of the millennial growth cycle will become the orphans of 2026: decent businesses, but no longer aligned with the parent’s priorities or growth algorithm.

2. Fewer Deals, Higher Conviction—and Still Full Valuations

If 2025 proved anything, it’s that lower deal volume does not automatically translate to lower pricing. In 2026, the market will likely remain defined by fewer transactions but more intentional ones—where buyers are underwriting not just category growth but also durable differentiation, margin defense, and the ability to scale efficiently. Quality assets will still command premium valuations, while “good but not great” brands will find the market increasingly thin.

3. Capability Acquisitions Will Accelerate

Beauty has entered a new innovation cycle—one increasingly shaped by biotech, ingredient science, advanced manufacturing, and next-generation packaging. As a result, investors will continue shifting capital toward the infrastructure behind the brands: manufacturers, labs, ingredient suppliers, and enabling technologies that power speed-to-market and product differentiation. Expect supply-side M&A to re-accelerate, as strategics and PE firms look to “buy-size” capabilities that future-proof their portfolios and provide leverage across multiple brands and categories.

4. Cross-Border Capital Will Be a Deal Driver

International interest in US beauty remains strong—particularly from Asian buyers—but many of these groups are disciplined and rarely overpay. That creates an opening for middle-of-the-road brands that may not attract a bidding war domestically but are attractive as strategic entry points. At the same time, capital flows will increasingly move in both directions: India became a major investment magnet in 2025, and the Middle East is emerging as a serious growth and innovation market. The value of the dollar will likely play into this trend—its decline in the early part of 2026 makes domestic deals slightly cheaper and international deals slightly more expensive—but this is prime arbitrage territory for global funds, platforms, and strategics.

5. The Market Will Split Between “Brand Winners” and “Execution Savants”

Capital will concentrate around two types of brands: those with exceptional lifestyle brand positioning and community-driven demand, and those with defensible moats—patents, proprietary technology, clinical proof, or unique IP. The other cohort attracting serious attention will be brands with execution advantages: vertical integration, owned distribution, superior margin structures, or operating leverage. The middle—the brands with great packaging, strong formulas, and strong growth but no defensible edge—will face the toughest funding and exit environment in years.

6. US Retail Will Continue to Pressure Brand Economics and Limit Luxury and Fragrance Deals

Retail has quietly become one of the biggest constraints on beauty growth and dealmaking. Consolidation has created an upper limit on shelf space at the exact moment the market has more brands than ever. With retailers holding exceptional leverage—and margin pressures rising—brands will face increasing demands around pricing, promotions, and trade spend. Luxury, in particular, has a structural bottleneck in the US: there are still too few viable distribution homes for luxury fragrance and other high-end brands, limiting both category expansion and exit optionality—and therefore limiting deal activity.

7. Beauty + Wellness Convergence Will Force New Underwriting Models

The beauty-wellness convergence is no longer just a talking point at conferences—it’s an investment thesis that’s now being funded in earnest. Longevity, devices, nutrition, services, and biotechnology will pull more capital into adjacent categories, but these assets require different diligence frameworks. Investors will need to adapt underwriting to account for clinical validation, research timelines, regulatory risk, IP defensibility, and claims scrutiny, introducing a new risk/reward profile that traditional beauty dealmakers have not historically had to price in.

8. The “Almost Deals” of 2024 + 2025 Will Retreat—and the Exit Playbook Will Expand

Many of the most anticipated deals of 2024 and 2025 that never materialized will go quiet in 2026. Instead of pushing into a soft or uncertain market, many brands will spend the year retrenching—tightening operations, strengthening leadership, diversifying revenue streams, and building growth in new geographies, channels, and customer segments. For the largest brands, exit optionality may narrow further; by 2027, some will be too big for traditional strategic buyers, increasing pressure for alternative exits—secondary buyouts, minority recapitalizations, or even public-market pathways (though, historically, the public markets have been dangerous for most beauty companies).

The throughline of 2025 beauty and wellness dealmaking was discipline. The market produced fewer deals, but the ones that got done were increasingly strategic—built around capability acquisition, margin defense, and long-term category positioning rather than short-term growth optics. At the same time, persistent brand failures underscored a harsher truth: beauty may be resilient, but the ecosystem is no longer forgiving, and capital can’t be relied on to cover up fundamental flaws in a business model. Heading into 2026, the winners will be the brands and investors who understand the new rules of value creation—where differentiation must be provable, distribution is harder earned, and the convergence of beauty and wellness demands a fundamentally different underwriting lens.

×

2 Article(s) Remaining

Subscribe today for full access